These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 18503889

  • 1. Vascular endothelial growth factor in chronic rat allograft nephropathy.
    Malmström NK, Kallio EA, Rintala JM, Nykänen AI, Räisänen-Sokolowski AK, Paavonen T, Lemström KB, Koskinen PK.
    Transpl Immunol; 2008 May; 19(2):136-44. PubMed ID: 18503889
    [Abstract] [Full Text] [Related]

  • 2. Vascular endothelial growth factor (VEGF) ligand and receptor induction in rat renal allograft rejection.
    Rintala SE, Savikko J, Rintala JM, von Willebrand E.
    Transplant Proc; 2006 Dec; 38(10):3236-8. PubMed ID: 17175233
    [Abstract] [Full Text] [Related]

  • 3. Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition.
    Zips D, Eicheler W, Geyer P, Hessel F, Dörfler A, Thames HD, Haberey M, Baumann M.
    Cancer Res; 2005 Jun 15; 65(12):5374-9. PubMed ID: 15958586
    [Abstract] [Full Text] [Related]

  • 4. Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor-3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts.
    Nykänen AI, Sandelin H, Krebs R, Keränen MA, Tuuminen R, Kärpänen T, Wu Y, Pytowski B, Koskinen PK, Ylä-Herttuala S, Alitalo K, Lemström KB.
    Circulation; 2010 Mar 30; 121(12):1413-22. PubMed ID: 20231530
    [Abstract] [Full Text] [Related]

  • 5. Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity.
    Yamamoto A, Watanabe H, Sueki H, Nakanishi T, Yasuhara H, Iijima M.
    J Dermatol; 2007 Jul 30; 34(7):419-29. PubMed ID: 17584317
    [Abstract] [Full Text] [Related]

  • 6. Expression of fractalkine, CX3CR1, and vascular endothelial growth factor in human chronic renal allograft rejection.
    Cao G, Lu Y, Gao R, Xin Y, Teng D, Wang J, Li Y.
    Transplant Proc; 2006 Sep 30; 38(7):1998-2000. PubMed ID: 16979977
    [Abstract] [Full Text] [Related]

  • 7. An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells.
    Lacal PM, Ruffini F, Pagani E, D'Atri S.
    Int J Oncol; 2005 Dec 30; 27(6):1625-32. PubMed ID: 16273219
    [Abstract] [Full Text] [Related]

  • 8. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis.
    Scaldaferri F, Vetrano S, Sans M, Arena V, Straface G, Stigliano E, Repici A, Sturm A, Malesci A, Panes J, Yla-Herttuala S, Fiocchi C, Danese S.
    Gastroenterology; 2009 Feb 30; 136(2):585-95.e5. PubMed ID: 19013462
    [Abstract] [Full Text] [Related]

  • 9. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.
    Clin Cancer Res; 2009 Mar 01; 15(5):1612-22. PubMed ID: 19223496
    [Abstract] [Full Text] [Related]

  • 10. VEGFR-1 and -2 regulate inflammation, myocardial angiogenesis, and arteriosclerosis in chronically rejecting cardiac allografts.
    Raisky O, Nykänen AI, Krebs R, Hollmén M, Keränen MA, Tikkanen JM, Sihvola R, Alhonen L, Salven P, Wu Y, Hicklin DJ, Alitalo K, Koskinen PK, Lemström KB.
    Arterioscler Thromb Vasc Biol; 2007 Apr 01; 27(4):819-25. PubMed ID: 17290032
    [Abstract] [Full Text] [Related]

  • 11. Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction.
    Ko HT, Yin JL, Wyburn K, Wu H, Eris JM, Hambly BD, Chadban SJ.
    Nephrol Dial Transplant; 2013 Feb 01; 28(2):327-36. PubMed ID: 23229928
    [Abstract] [Full Text] [Related]

  • 12. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1.
    Hazarika S, Dokun AO, Li Y, Popel AS, Kontos CD, Annex BH.
    Circ Res; 2007 Oct 26; 101(9):948-56. PubMed ID: 17823371
    [Abstract] [Full Text] [Related]

  • 13. FK778 ameliorates post-transplant expression of fibrogenic growth factors and development of chronic rejection changes in rat kidney allografts.
    Rintala JM, Savikko J, Rintala SE, von Willebrand E.
    Nephrol Dial Transplant; 2008 Nov 26; 23(11):3446-55. PubMed ID: 18558624
    [Abstract] [Full Text] [Related]

  • 14. Comprehensive immunohistological analysis of the endothelin system in human kidney grafts.
    Frank K, Zeier M, Gross ML, Waldherr R, Ritz E, Amann K.
    Nephrol Dial Transplant; 2006 May 26; 21(5):1365-72. PubMed ID: 16449275
    [Abstract] [Full Text] [Related]

  • 15. Differential regulation of vascular endothelial growth factor receptors (VEGFR) revealed by RNA interference: interactions of VEGFR-1 and VEGFR-2 in endothelial cell signaling.
    Kou R, SenBanerjee S, Jain MK, Michel T.
    Biochemistry; 2005 Nov 15; 44(45):15064-73. PubMed ID: 16274253
    [Abstract] [Full Text] [Related]

  • 16. A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability.
    Patel N, Sun L, Moshinsky D, Chen H, Leahy KM, Le P, Moss KG, Wang X, Rice A, Tam D, Laird AD, Yu X, Zhang Q, Tang C, McMahon G, Howlett A.
    J Pharmacol Exp Ther; 2003 Sep 15; 306(3):838-45. PubMed ID: 12766257
    [Abstract] [Full Text] [Related]

  • 17. Vascular endothelial growth factor plays a major role in development of experimental obliterative bronchiolitis.
    Krebs R, Hollmén ME, Tikkanen JM, Wu Y, Hicklin DJ, Koskinen PK, Lemström KB.
    Transplant Proc; 2006 Dec 15; 38(10):3266-7. PubMed ID: 17175244
    [Abstract] [Full Text] [Related]

  • 18. Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells.
    Balthasar S, Bergelin N, Löf C, Vainio M, Andersson S, Törnquist K.
    Endocr Relat Cancer; 2008 Jun 15; 15(2):521-34. PubMed ID: 18509004
    [Abstract] [Full Text] [Related]

  • 19. VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice.
    Ou XM, Li WC, Liu DS, Li YP, Wen FQ, Feng YL, Zhang SF, Huang XY, Wang T, Wang K, Wang X, Chen L.
    Int Immunopharmacol; 2009 Jan 15; 9(1):70-9. PubMed ID: 18976720
    [Abstract] [Full Text] [Related]

  • 20. Vascular endothelial growth factor receptor-1 regulates postnatal angiogenesis through inhibition of the excessive activation of Akt.
    Nishi J, Minamino T, Miyauchi H, Nojima A, Tateno K, Okada S, Orimo M, Moriya J, Fong GH, Sunagawa K, Shibuya M, Komuro I.
    Circ Res; 2008 Aug 01; 103(3):261-8. PubMed ID: 18583712
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.